Genocea Biosciences, Inc. (GNCA)
$0.0001
Rating:
Recommendation:
Buy
| Symbol | GNCA |
|---|---|
| Price | $0.0001 |
| Beta | 0.000 |
| Volume Avg. | 0.08M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 1.0E-4-1.45 |
| 1y Target Est | - |
| DCF Unlevered | GNCA DCF -> | |
|---|---|---|
| DCF Levered | GNCA LDCF -> | |
| ROE | -182.88% | Strong Sell |
| ROA | -95.88% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 213.19% | Strong Buy |
| P/E | - | |
| P/B | 0 | Neutral |
Latest GNCA news
About
Download (Excel)Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.